Every year, promising drug candidates move into clinical trials only to be flagged for potential drug-induced liver injury (DILI) risk. Millions of dollars and countless hours of research have been poured into therapies that end up shelved or dumped—but until now, there’s been no way to anticipate DILI risk earlier in the drug development process.
Enter Liver Safety+.